Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.64 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.64 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.64 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.64 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.64 |
| ▸ | NAMPT | P43490 | 1/20 | 0.52 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10116668 | 0.85 | NPC1 (0.56) | LMNAKDM4EALDH1A1TP53MAPT | |
| SCHEMBL10116705 | 0.85 | PTPN1 (0.52) | LMNAKDM4EMAPTSMN1; SMN2 | |
| SCHEMBL10116764 | 0.84 | LMNA (0.47) | HDAC8HDAC6HDAC3HDAC11DEGS1 | |
| SCHEMBL10116418 | 0.83 | HDAC8 (0.64) | HDAC8HDAC6HDAC3HDAC11DEGS1 | |
| SCHEMBL10116688 | 0.82 | LMNA (0.48) | LMNAKDM4EALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL10116675 | 0.81 | LMNA (0.58) | LMNAKDM4EALDH1A1TP53SMN1; SMN2 | |
| SCHEMBL10116661 | 0.81 | LMNA (0.49) | LMNAKDM4EALDH1A1TP53MAPT | |
| SCHEMBL10116768 | 0.81 | HDAC3 (0.44) | HDAC8HDAC6HDAC3HDAC11DEGS1 | |
| SCHEMBL16022191 | 0.80 | HDAC8 (0.76) | HDAC8HDAC6HDAC3HDAC11DEGS1 | |
| SCHEMBL10116627 | 0.80 | LMNA (0.56) | NAMPTLMNAKDM4EALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8115027-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2012-02-14 | — | — | US | disclosed |
| US-8115027-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2012-02-14 | — | — | US | disclosed |
| US-20110039802-A1 | NPY Y5 ANTAGONIST | KAWANISHI YASUYUKI | 2011-02-17 | — | — | US | disclosed |
| US-20100292500-A1 | NPY Y5 ANTAGONIST | KAWANISHI YASUYUKI | 2010-11-18 | — | — | US | disclosed |
| US-20100292500-A1 | NPY Y5 ANTAGONIST | KAWANISHI YASUYUKI | 2010-11-18 | — | — | US | disclosed |
| US-7781461-B2 | NPY Y5 antagonist | KAWANISHI YASUYUKI | 2010-08-24 | — | — | US | disclosed |
| US-7781461-B2 | NPY Y5 antagonist | KAWANISHI YASUYUKI | 2010-08-24 | — | — | US | disclosed |
| US-7265130-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2007-09-04 | — | — | US | disclosed |
| US-7265130-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2007-09-04 | — | — | US | disclosed |
| US-20070015762-A1 | NPY Y5 antagonist | KAWANISHI YASUYUKI | 2007-01-18 | — | — | US | disclosed |
| US-20070015762-A1 | NPY Y5 antagonist | KAWANISHI YASUYUKI | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015762-A1 | NPY Y5 antagonist | NPY5R, NPY1R, NPY2R | HDAC8 706/4885HDAC6 1853/4885HDAC3 664/4885 |
| US-20100292500-A1 | NPY Y5 ANTAGONIST | NPY5R, NPY1R, NPY2R | HDAC8 634/4885HDAC6 1602/4885HDAC3 489/4885 |
| US-20110039802-A1 | NPY Y5 ANTAGONIST | NPY5R, NPY1R, NPY2R | HDAC8 743/4885HDAC6 1849/4885HDAC3 669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.